In fact, the phase I study NCT01348347 recently concluded with positive results about overall tolerability, safety and clinical benefits of the oral PLK inhibitor Volasertib in patients with advanced CCA [176,177]. The gene discussed is PLK1; the disease is cholangiocarcinoma.